1 |
Kim M., Lee Y. S., Mathew H. L., and Wurster R. D. (1997) Induction of apoptotic cell death in a neuroblastoma cell line by dibucaine. Exp. Cell Res. 231, 235-241
DOI
ScienceOn
|
2 |
Lee R. H., Song J. M., Park M. Y., Kang S. K., Kim Y. K., and Jung J. S. (2001) Cisplatin-induced apoptosis by translocation of endogenous BAX in mouse collecting duct cells. Biochem. Pharmacol. 62, 1013-1023
DOI
ScienceOn
|
3 |
Li J., Feng Q., Kim J. M., Schneidernlan D., Liston P., Li M., Vanderhyden B., Faught W., Fung M. F., Senterman M., Korneluk R. G., and Tsang B. K. (2001) Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142, 370-380
DOI
ScienceOn
|
4 |
Breitschopf K., Haendeler J., Malchow P., Zeiher A. M., and Dimrneler S. (2000) Posttranslational modification of Bc1-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol.Cell BioI. 20, 1886-1896
DOI
ScienceOn
|
5 |
Chao D. T., and Korsmeyer S. J. (1998) Bc1-2 family: Regulators of cell death. Annual Rev. Immunol. 16, 395-419
DOI
ScienceOn
|
6 |
Chu G. (1994) Cellular responses to cisplatin. The roles of DNA binding proteins and DNA repair. J. BioI. Chem. 269, 787-790
|
7 |
Okazaki Y., Miura N., Satoh M., Imura N., and Naganuma A. (1998) Metallothionein-'mediated resistance to multiple drugs can be induced by several anticancer drug in mice. Biochem. Biophys. Res. Commun. 245, 815-818
DOI
ScienceOn
|
8 |
Oltvai Z. N., Milliman C. L., and Korsmeyer S. J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619
DOI
ScienceOn
|
9 |
Perez R. P. (1998) Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34, 1535-1542,
DOI
ScienceOn
|
10 |
Reed J. C. (1998) Bcl-2 family proteins. Oncogene 17, 3225-3236
DOI
ScienceOn
|
11 |
Gonzalez·V. M., Fuertes M. A, Alonso C., and Perez J. M. (2001) Is Cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663
|
12 |
Harris M. H., and Thompson C. B. (2000) The role of the BcI-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7, 1182-1191
DOI
ScienceOn
|
13 |
Huang L., Sowa Y., and Pardee A. B. (2000) Activation of the p21WAFI/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Spl sites. Oncogene 19, 5712-5719
DOI
ScienceOn
|
14 |
Joncourt F., Buser K., Altermatt H., Bacchi M., Oberli A., Cerny T. (1998) Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol. 70, 176-182
|
15 |
Kamarajan P., Sun N. K., Sun C. L., and Chao C. C. (2001) ApafI overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS Lett. 505, 206-212
DOI
ScienceOn
|
16 |
Liu P. Q., Liu C. E., and Ames G. F. (1999) Modulation of ATPase activity by physical disengagement of the ATP-binding domains of an ABC transporter, the histidine permease. J. Biol. Chem. 274, 18310-18318
DOI
|
17 |
Kartner N., Everden-Porelle D., Bradley G., and Ling V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoelonal antibodies. Nature 316, 820-823
DOI
ScienceOn
|
18 |
Liu J. R., Fletcher B., Page C., Hu C., Nunez G., and Baker V. (1998) Bel-X is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70, 398-403
|
19 |
Liu J. R, Opipari A. W., Tan L., Jiang Y., Zhang Y., Tang H., and Nunez G. (2002) Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance. Cancer Res. 62, 924-931
|
20 |
Miyashita T., and Reed J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 80, 293-299
DOI
ScienceOn
|
21 |
Timrner-Bosscha H., Mulder N. H., and de Vries E. G. (1992) Modulation of cis-diamininedichloroplatinum(II) resistance: a review. Br. J. Cancer 66, 227-238
DOI
ScienceOn
|
22 |
Nagane M., Levitzki A., Gazit A., Gavenee W. K., and Huang H.-J. S. (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-X and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95, 5724-5729
DOI
|
23 |
Nomura M., Shimizu S., Ito T., Narita M., Matsuda H., and Tsujimoto Y. (1999) Apoptotic cytosol facilitates Bax translocation to mitochondrial that involves cytosolic factor regulated by Bcl-2. Cancer Res. 59, 5542-5548
|
24 |
Reed J. C. (2000) Mechanisms of apoptosis. Am. J. Pathol. 157, 1415-1430
DOI
ScienceOn
|
25 |
Walker P. R., Leblanc J., Smith B., Pandey S., and Sikorska M. (1999) Detection of DNA fragmentation and endonuclease in apoptosis. Methods 17, 329-338
DOI
ScienceOn
|
26 |
Finucane D. M., Bossy-Wetzel E., Waterhouse N. J., Cotter T. G., and Green D. R. (1999) Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-X. J. Bioi Chem. 274, 2225-2233
DOI
ScienceOn
|
27 |
Ganju N., and Eastman A. (2002) Bel-X and Calyculin A prevent translocation of Bax to mitochondria during apoptosis. Biochem. Biophys. Res. Commun. 291, 1258-1264
DOI
ScienceOn
|
28 |
Germann U. A (1996) P-glycoprotein A mediator of multidrug resistance in tumour cells. Eur. J. Cancer 324, 927-944
|
29 |
el-Deiry W. S. (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curro Opin. Oncol. 9, 79-87
|